Category Research

Exact Sciences Highlights the Impact of Oncotype DX® and Genomic Insights at SABCS 2024 Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, will present a robust array of new data at the 2024 San Antonio Breast Cancer Symposium®…

Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, has announced the integration of its advanced AI solutions into routine clinical practice at Institut Curie, one of the world’s most renowned cancer centers. Pathologists at Institut Curie are now…

Eli Lilly and Company (NYSE: LLY) has revealed encouraging Phase 2 results for muvalaplin, an investigational once-daily oral inhibitor targeting lipoprotein(a) [Lp(a)], a hereditary risk factor for cardiovascular disease. The trial demonstrated that muvalaplin significantly lowered elevated Lp(a) levels, achieving…

Ipsen (Euronext: IPN; ADR: IPSEY) presented new data at the American Association for the Study of Liver Diseases (AASLD) from two Phase III open-label extension studies, evaluating the long-term efficacy and safety of Bylvay® in patients with Progressive Familial Intrahepatic…

Halozyme Therapeutics, Inc. (NASDAQ: HALO) has provided an update regarding its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) for €11.00 per share in cash, valuing the transaction at approximately €2.0 billion. A presentation on Halozyme’s investor relations website outlines…

Brenus Pharma has announced the publication of a scientific article in Frontiers in Oncology detailing the results of its novel “off-the-shelf” cancer treatment. The company’s innovative platform replicates patients’ relapsing conditions in the lab to train the immune system to…

Care Access, a global clinical research company focused on advancing medicine, is hosting a Heart & Kidney Health Screening event in Houston, Texas. The initiative is designed to raise awareness about health risks, including lipoprotein(a) [Lp(a)], a harmful type of…

Tempus AI, Inc. (NASDAQ: TEM), a leader in utilizing AI to advance precision medicine and patient care, announced today that nine abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place…

Gilead Sciences, Inc. (Nasdaq: GILD) has announced the upcoming presentation of over 40 HIV research studies at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The research includes late-breaking findings, with…

BridgeBio Pharma, Inc. (Nasdaq: BBIO), an innovative biopharmaceutical company focused on treating genetic diseases, has announced the publication of a case study, “Applications of Portfolio Theory to Accelerating Biomedical Innovation,” in The Journal of Portfolio Management. This study, which highlights…